Role of epinephrine stimulation of CNS alpha1-adrenoceptors in motor activity in mice.
The role of brain epinephrine (EPI) in the regulation of motor activity and movement in mice was examined. Blockade of EPI synthesis with i.p. 2,3-dichloro-alpha-methylbenzylamine (DCMB) or LY134046 was found to produce marked behavioral inactivity which could be significantly reversed by intraventricular injection of EPI and by three other alpha(1)-adrenoceptor agonists, norepinephrine (NE), 6-fluoronorepinephrine (6FNE), and phenylephrine (PE), as well as by serotonin (5HT). EPI had the largest effect of these agonists and also was the only one that reversed nondrug-induced inactivity of mice in their home cages during the light phase. The effects of EPI were blocked by coinfusion of an alpha(1)-adrenoceptor antagonist (terazosin) but not of an alpha(2)-(atipamezole) or beta(1) (betaxolol)-blocker. The rank order of maximal behavioral responses to EPI, 6FNE, and PE in DCMB-treated mice was the same as the rank order of their maximal stimulation of hydrolysis of phosphatidylinositol at cloned alpha(1B)-adrenoceptors in cell culture. On the basis of the above findings and of the central distributions of adrenergic neurons and alpha(1)-adrenoceptors, the existence of a central EPI-innervated alpha(1)-adrenergic receptor system is postulated which serves to coexcite or enhance signaling in several monoaminergic brain regions involved in movement and motor activity.
Stone
Eric A
EA
Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA. es35@nyu.edu
Grunewald
Gary L
GL
Lin
Yan
Y
Ahsan
Rashedul
R
Rosengarten
Helen
H
Kramer
H Kenneth
HK
Quartermain
David
D
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001596:Benzylamines / Q000494:pharmacology; D015784:Betaxolol / Q000494:pharmacology; D001921:Brain / Q000187:drug effects*; D002460:Cell Line; D004837:Epinephrine / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D006801:Humans; D006868:Hydrolysis; D007093:Imidazoles / Q000494:pharmacology; D007276:Injections, Intraventricular; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects*; D009638:Norepinephrine / Q000031:analogs & derivatives* / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D010716:Phosphatidylinositols / Q000378:metabolism; D011224:Prazosin / Q000031:analogs & derivatives* / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000378:metabolism*; D012701:Serotonin / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D001596:Benzylamines; D007093:Imidazoles; D010716:Phosphatidylinositols; D011942:Receptors, Adrenergic, alpha; C050701:atipamezole; D010656:Phenylephrine; D012701:Serotonin; C002569:2,3-dichloro-alpha-methylbenzylamine; C024884:6-fluoronorepinephrine; C041226:Terazosin; D015784:Betaxolol; D009638:Norepinephrine; D011224:Prazosin; D004837:Epinephrine